TY  - JOUR
AU  - Worst, Barbara
AU  - van Tilburg, Cornelis Martinus
AU  - Balasubramanian, Gnana Prakash
AU  - Fiesel, Petra
AU  - Witt, Ruth
AU  - Freitag, Angelika
AU  - Boudalil, Miream
AU  - Previti, Christopher
AU  - Wolf, Stephan
AU  - Schmidt, Sabine
AU  - Chotewutmontri, Sasithorn
AU  - Bewerunge-Hudler, Melanie
AU  - Schick, Matthias
AU  - Schlesner, Matthias
AU  - Hutter, Barbara
AU  - Taylor, Lenka
AU  - Borst, Tobias
AU  - Sutter, Christian
AU  - Bartram, Claus R
AU  - Milde, Till
AU  - Pfaff, Elke
AU  - Kulozik, Andreas E
AU  - von Stackelberg, Arend
AU  - Meisel, Roland
AU  - Borkhardt, Arndt
AU  - Reinhardt, Dirk
AU  - Klusmann, Jan-Henning
AU  - Fleischhack, Gudrun
AU  - Tippelt, Stephan
AU  - Dirksen, Uta
AU  - Jürgens, Heribert
AU  - Kramm, Christof M
AU  - von Bueren, Andre O
AU  - Westermann, Frank
AU  - Fischer, Matthias
AU  - Burkhardt, Birgit
AU  - Wößmann, Wilhelm
AU  - Nathrath, Michaela
AU  - Bielack, Stefan S
AU  - Frühwald, Michael C
AU  - Fulda, Simone
AU  - Klingebiel, Thomas
AU  - Koscielniak, Ewa
AU  - Schwab, Matthias
AU  - Tremmel, Roman
AU  - Driever, Pablo Hernáiz
AU  - Schulte, Johannes H
AU  - Brors, Benedikt
AU  - von Deimling, Andreas
AU  - Lichter, Peter
AU  - Eggert, Angelika
AU  - Capper, David
AU  - Pfister, Stefan
AU  - Jones, David
AU  - Witt, Olaf
TI  - Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
JO  - European journal of cancer
VL  - 65
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2017-06049
SP  - 91 - 101
PY  - 2016
AB  - The Individualized Therapy for Relapsed Malignancies in Childhood (INFORM) precision medicine study is a nationwide German program for children with high-risk relapsed/refractory malignancies, which aims to identify therapeutic targets on an individualised basis. In a pilot phase, reported here, we developed the logistical and analytical pipelines necessary for rapid and comprehensive molecular profiling in a clinical setting. Fifty-seven patients from 20 centers were prospectively recruited. Malignancies investigated included sarcomas (n = 25), brain tumours (n = 23), and others (n = 9). Whole-exome, low-coverage whole-genome, and RNA sequencing were complemented with methylation and expression microarray analyses. Alterations were assessed for potential targetability according to a customised prioritisation algorithm and subsequently discussed in an interdisciplinary molecular tumour board. Next-generation sequencing data were generated for 52 patients, with the full analysis possible in 46 of 52. Turnaround time from sample receipt until first report averaged 28 d. Twenty-six patients (50
LB  - PUB:(DE-HGF)16
C6  - pmid:27479119
DO  - DOI:10.1016/j.ejca.2016.06.009
UR  - https://inrepo02.dkfz.de/record/130973
ER  -